B Braun Medical, a provider of smart infusion therapy and pain management solutions, has introduced the new CARESITE Micro Luer Access Device.
The device is designed to enhance the safety of intravenous (IV) access for both patients and healthcare providers by minimising exposure to dangerous chemicals and reducing the risk of infection.
It has a flat and smooth surface for easy disinfection and a straight fluid path design to completely flush blood and medications using a small flush volume, thereby lowering the risk of hospital-acquired bloodstream infections (HA-BSIs).
Commonly linked to catheter insertions, HA-BSIs continue to be a significant cause of morbidity and mortality.
The device is claimed to be the only needleless connector produced without the use of Bisphenol A (BPA), a harmful chemical which causes multi-organ toxicity.
Produced using material resistant to drugs, the CARESITE Micro Device can reduce infections and drug exposure risk caused by stress cracks related to material and drug incompatibility.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
B Braun Medical Affairs corporate vice-president Angela Karpf said: “We are excited to introduce the CARESITE Micro Luer Access Device. Helping to reduce HA-BSIs and accidental drug exposure supports our commitment to the safety of the patients and providers we serve.”
Last month, B Braun Medical issued a product recall correction of its Infusomat Space Volumetric Infusion Pump System, including the Infusomat Space Large Volume Pump, Wireless and Infusomat Space Large Volume Pump, and Non-Wireless BATTERY PACK.
After receiving 51 complaints, one reported injury, and one death, the US Food and Drug Administration classified the recall as a Class I recall, indicating a significant risk of injury and death associated with the devices.
